Inclusion Criteria:  Participant clinically or pathologically diagnosed with KHE, TA or complicated superficial vascular anomolies involving lymphatic components.  The case is initial, with a relatively limited superficial lesion. The participant has residual surface lesions after oral medication. Participant with no use of other medication or surgical treatment Participant with detailed medical records of the disease at the time of screening Participant with signed and dated informed consent from the guardian(s)  Exclusion Criteria:  Participants with Kasabach-Merritt Phenomenon, with platelets <50×10 9 /L. Participants with general disease such as hypertension, diabetes, adrenal insufficiency, neurological diseases, liver and kidney dysfunction, and cardiopulmonary insufficiency. Participants with other hematological diseases or solid tumor. Participants allergic to sirolimus or dressing.